Skip to main content

Table 1 Clinical parameters of the study subjects

From: Circular RNA ciRs-126 promotes hypoxia/reoxygenation cardiac injury possibly through miR-21

Clinical parameters H/R (n = 60) Healthy subjects (n = 60) P
Sex (male/female) 30/30 30/30 1.000
Age (years) 52.1±6.7 52.0±6.8 0.643
Tobacco 72% (43) 58% (35) 0.091
Hypertension 76% (46) 0
Hypercholesterolemia 77% (46) 0
Diabetes mellitus 31% (19) 0
Body mass index (kg/m2) 23 ± 2,2 22 ± 1.8 0.000
Previous MI 6% (4) 0
Previous CABG 1.6% (1) 0
Previous PTCA 0 0  
Glucose (mmol/L) 3.1 ± 1.1 3.5 ± 0.2 0.000
High-sensitivity C-reactive protein (mg/L) 15.13 ± 6.66 1.89 ± 1.36 0.000
LDH (U/L) 481.60 ± 55.73 157.71 ± 22.94 0.000
CK-MB (U/L) 118.29 ± 55.63 10.11 ± 2.16 0.000
cTnT (µg/L) 21.44 ±5.95 0
Aspirin use 56% (34) 0
Clopidogrel use 42% (25) 0
Beta blocker use 84% (50) 0
Nitrates use 77% (46) 0
Angiotensin-converting-enzyme inhibitor drugs use 30% (18) 0
Angiotensin receptor blocker use 11% (7) 0
Calcium channel blocker use 9% (5) 0
Lipid-lowering drugs 68% 0
  1. CABG: coronary artery bypass graft; PTCA: percutaneous transluminal coronary angioplasty; LDH: lactate dehydrogenase; CK-MB: creatine kinase-MB; cTnT: cardiac troponin T. P (controls VS. HR)